Provided by Tiger Trade Technology Pte. Ltd.

Phathom Pharmaceuticals

8.87
+0.27003.14%
Post-market: 8.85-0.0235-0.26%19:34 EDT
Volume:979.41K
Turnover:8.64M
Market Cap:717.59M
PE:-7.01
High:8.90
Open:8.63
Low:8.59
Close:8.60
52wk High:18.31
52wk Low:8.21
Shares:80.90M
Float Shares:63.93M
Volume Ratio:0.93
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2659
EPS(LYR):-3.0342
ROE:-3489.00%
ROA:-8.80%
PB:-2.08
PE(LYR):-2.92

Loading ...

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Aug 17

Phathom Pharmaceuticals’ Earnings Call Signals Profitable Growth

TIPRANKS
·
Aug 16

Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough

Simply Wall St.
·
Aug 01

Phathom Pharmaceuticals is Maintained at Buy by Needham

Dow Jones
·
Jul 31

Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham

TIPRANKS
·
Jul 31

Phathom Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Phathom Pharmaceuticals Down over 19%, on Track for Largest Percent Decrease Since May 2025

Dow Jones
·
Jul 31

Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth

Reuters
·
Jul 30

Phathom Q2 GAAP Net Loss Narrows to $17.6 Million from Year-ago; Revenue Rises 88% to $74.3 Million

Reuters
·
Jul 30

Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate

Benzinga Earnings
·
Jul 30

Phathom Pharmaceuticals Outlook FY Revenue USD 310-325 Million VS. Ibes Estimate USD 332.2 Million

THOMSON REUTERS
·
Jul 30

Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million

THOMSON REUTERS
·
Jul 30

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
Jul 30

Phathom Pharma Schedules Second-quarter Earnings Webcast

Reuters
·
Jul 20

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

GlobeNewswire
·
Jul 20

Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 25

Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial

TIPRANKS
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna

MT Newswires Live
·
Jun 23

Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults

Reuters
·
Jun 23

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)

THOMSON REUTERS
·
Jun 23